These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20922406)

  • 1. A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.
    Grabellus F; Sheu SY; Bauer S; Speich N; Schmid KW; Worm K
    Virchows Arch; 2010 Nov; 457(5):623-5. PubMed ID: 20922406
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
    J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
    Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K
    Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507
    [No Abstract]   [Full Text] [Related]  

  • 5. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.
    Rössle M; Hirschmann A; Diebold J
    Eur J Cancer; 2011 Jun; 47(9):1305-11. PubMed ID: 21334201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis and management of gastrointestinal stromal tumors.
    Bayraktar UD; Bayraktar S; Rocha-Lima CM
    World J Gastroenterol; 2010 Jun; 16(22):2726-34. PubMed ID: 20533592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
    Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumors, version 2.2014.
    von Mehren M; Randall RL; Benjamin RS; Boles S; Bui MM; Casper ES; Conrad EU; DeLaney TF; Ganjoo KN; George S; Gonzalez RJ; Heslin MJ; Kane JM; Mayerson J; McGarry SV; Meyer C; O'Donnell RJ; Pappo AS; Paz IB; Pfeifer JD; Riedel RF; Schuetze S; Schupak KD; Schwartz HS; Van Tine BA; Wayne JD; Bergman MA; Sundar H
    J Natl Compr Canc Netw; 2014 Jun; 12(6):853-62. PubMed ID: 24925196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
    Blay JY; Reichardt P
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Reichardt P; Reichardt A
    Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
    Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S; Jia J; Pan YL; Tao DY; Lu HS
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
    [No Abstract]   [Full Text] [Related]  

  • 18. When a thymic carcinoma "becomes" a GIST.
    Rossi V; Donini M; Sergio P; Passalacqua R; Rossi G; Buti S
    Lung Cancer; 2013 Apr; 80(1):106-8. PubMed ID: 23375402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].
    Agaimy A; Schneider-Stock R
    Pathologe; 2010 Mar; 31(2):115-22. PubMed ID: 19949796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumors of the stomach.
    Bennett JJ; Rubino MS
    Surg Oncol Clin N Am; 2012 Jan; 21(1):21-33. PubMed ID: 22098829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.